240 related articles for article (PubMed ID: 12847521)
21. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G
Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011
[TBL] [Abstract][Full Text] [Related]
22. The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.
Lu QL; Yokota T; Takeda S; Garcia L; Muntoni F; Partridge T
Mol Ther; 2011 Jan; 19(1):9-15. PubMed ID: 20978473
[TBL] [Abstract][Full Text] [Related]
23. Dystrophin: the protein product of the Duchenne muscular dystrophy locus.
Hoffman EP; Brown RH; Kunkel LM
Cell; 1987 Dec; 51(6):919-28. PubMed ID: 3319190
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD).
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):92-5. PubMed ID: 26086759
[No Abstract] [Full Text] [Related]
25. Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.
O'Donovan L; Okamoto I; Arzumanov AA; Williams DL; Deuss P; Gait MJ
Nucleic Acid Ther; 2015 Feb; 25(1):1-10. PubMed ID: 25412073
[TBL] [Abstract][Full Text] [Related]
26. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
[TBL] [Abstract][Full Text] [Related]
27. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.
Wu B; Lu P; Cloer C; Shaban M; Grewal S; Milazi S; Shah SN; Moulton HM; Lu QL
Am J Pathol; 2012 Aug; 181(2):392-400. PubMed ID: 22683468
[TBL] [Abstract][Full Text] [Related]
28. Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model.
Heemskerk H; de Winter C; van Kuik P; Heuvelmans N; Sabatelli P; Rimessi P; Braghetta P; van Ommen GJ; de Kimpe S; Ferlini A; Aartsma-Rus A; van Deutekom JC
Mol Ther; 2010 Jun; 18(6):1210-7. PubMed ID: 20407428
[TBL] [Abstract][Full Text] [Related]
29. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
Goyenvalle A; Babbs A; Powell D; Kole R; Fletcher S; Wilton SD; Davies KE
Mol Ther; 2010 Jan; 18(1):198-205. PubMed ID: 19844193
[TBL] [Abstract][Full Text] [Related]
30. PTC124 targets genetic disorders caused by nonsense mutations.
Welch EM; Barton ER; Zhuo J; Tomizawa Y; Friesen WJ; Trifillis P; Paushkin S; Patel M; Trotta CR; Hwang S; Wilde RG; Karp G; Takasugi J; Chen G; Jones S; Ren H; Moon YC; Corson D; Turpoff AA; Campbell JA; Conn MM; Khan A; Almstead NG; Hedrick J; Mollin A; Risher N; Weetall M; Yeh S; Branstrom AA; Colacino JM; Babiak J; Ju WD; Hirawat S; Northcutt VJ; Miller LL; Spatrick P; He F; Kawana M; Feng H; Jacobson A; Peltz SW; Sweeney HL
Nature; 2007 May; 447(7140):87-91. PubMed ID: 17450125
[TBL] [Abstract][Full Text] [Related]
31. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
[TBL] [Abstract][Full Text] [Related]
32. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
33. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
[TBL] [Abstract][Full Text] [Related]
34. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.
Goemans N; Mercuri E; Belousova E; Komaki H; Dubrovsky A; McDonald CM; Kraus JE; Lourbakos A; Lin Z; Campion G; Wang SX; Campbell C;
Neuromuscul Disord; 2018 Jan; 28(1):4-15. PubMed ID: 29203355
[TBL] [Abstract][Full Text] [Related]
35. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
36. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski Z; Kole R
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8673-7. PubMed ID: 8378346
[TBL] [Abstract][Full Text] [Related]
37. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotide therapy for neurodegenerative disease.
Smith RA; Miller TM; Yamanaka K; Monia BP; Condon TP; Hung G; Lobsiger CS; Ward CM; McAlonis-Downes M; Wei H; Wancewicz EV; Bennett CF; Cleveland DW
J Clin Invest; 2006 Aug; 116(8):2290-6. PubMed ID: 16878173
[TBL] [Abstract][Full Text] [Related]
39. Dystrophin and mutations: one gene, several proteins, multiple phenotypes.
Muntoni F; Torelli S; Ferlini A
Lancet Neurol; 2003 Dec; 2(12):731-40. PubMed ID: 14636778
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.
Yokota T; Lu QL; Partridge T; Kobayashi M; Nakamura A; Takeda S; Hoffman E
Ann Neurol; 2009 Jun; 65(6):667-76. PubMed ID: 19288467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
